Table 2.
Propensity-weighted prostate cancer symptoms indices scores for sexual, urinary, and bowel symptoms across different treatment groups at baseline, and at 3, 12, and 24 months
| Active surveillance | EBRT without ADT | SBRT | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients | Mean score (SD) |
No. of patients | Mean score (SD) |
Mean difference score vs active surveillance (95% CI) |
No. of patients | Mean score (SD) |
Mean difference score vs active surveillance (95% CI) |
|
| Sexual dysfunction | ||||||||
| Baseline | 382 | 44.7 (38.0) |
182 | 43.6 (55.6) |
−1.0 (−8.1, 6.1) |
100 | 44.2† (67.3) |
−0.5 (−12.1, 11.1) |
| 3 months | 299 | 45.5 (38.9) |
134 | 53.5 (55.2) |
8.0* (0.5, 15.6) |
95 | 43.2† (65.7) |
−2.2 (−13.6, 9.1) |
| 12 months | 272 | 48.3 (37.5) |
128 | 51.3 (52.9) |
3.0 (−4.3, 10.3) |
92 | 51.2† (65.2) |
2.8 (−8.5, 14.2) |
| 24 months | 233 | 56.7 (38.1) |
117 | 55.5 (52.4) |
−1.2 (−8.7, 6.3) |
74 | 52.9† (62.5) |
−3.9 (−15.7, 8.0) |
| Urinary obstruction/irritation | ||||||||
| Baseline | 379 | 23.4 (14.0) |
182 | 22.9 (21.5) |
−0.5 (−3.4, 2.3) |
102 | 20.9 (23.9) |
−2.5 (−6.7, 1.6) |
| 3 months | 298 | 23.6 (13.1) |
140 | 34.4 (27.3) |
10.8* (7.5, 14.2) |
95 | 20.5 (33.0) |
−3.1 (−7.1, 1.0) |
| 12 months | 278 | 26.6 (15.5) |
129 | 24.5 (20.3) |
−2.0 (−5.0, 0.9) |
94 | 26.1 (38.6) |
−0.4 (−5.9, 5.1) |
| 24 months | 225 | 25.7 (14.3) |
120 | 24.4 (21.4) |
−1.3 (−4.6, 2.1) |
78 | 25.6 (28.0) |
0 (−6.6, 6.5) |
| Urinary incontinence | ||||||||
| Baseline | 379 | 11.1 (20.7) |
182 | 10.7 (29.9) |
−0.3 (−4.0, 3.3) |
102 | 12.0 (33.9) |
1.0 (−5.4, 7.4) |
| 3 months | 301 | 12.6 (20.8) |
136 | 16.7 (34.5) |
4.0 (−0.5, 8.6) |
95 | 12.3 (31.3) |
−0.4 (−5.5, 4.8) |
| 12 months | 276 | 14.5 (22.6) |
130 | 15.1 (33.8) |
0.7 (−4.2, 5.5) |
94 | 17.3 (43.6) |
2.8 (−5.3, 11.0) |
| 24 months | 230 | 17.8 (23.8) |
120 | 17.8 (35.0) |
−0.1 (−5.2, 5.1) |
79 | 11.9 (36.9) |
−5.9 (−12.5, 0.7) |
| Bowel problems | ||||||||
| Baseline | 387 | 6.1 (8.3) |
182 | 5.8 (12.1) |
−0.3 (−1.8, 1.1) |
102 | 4.4 (12.5) |
−1.7 (−3.8, 0.4) |
| 3 months | 302 | 7.3 (9.8) |
140 | 11.9 (21.2) |
4.6* (2.0, 7.3) |
97 | 4.9 (11.8) |
−2.4* (−4.4, −0.5) |
| 12 months | 279 | 7.5 (10.4) |
130 | 9.5 (19.0) |
2.0 (−0.5, 4.5) |
95 | 4.7 (13.5) |
−2.8* (−5.1, −0.5) |
| 24 months | 233 | 6.5 (7.2) |
120 | 9.7 (21.4) |
3.2* (0.2, 6.2) |
79 | 4.0 (9.3) |
−2.5* (−4.3, −0.7) |
Domain scores range from 0 to 100, with higher score indicating worse symptoms.
*
Statistically significant difference vs active surveillance.
†
Analysis of the Sexual Dysfunction score for SBRT patients excluded 2 outliers who required very high propensity weights if included in the analysis.
Abbreviations: EBRT, external beam radiation therapy; ADT, androgen deprivation therapy; SBRT, stereotactic body radiotherapy; SD, standard deviation; CI, confidence interval